Trial Profile
A retrospective multicenter to determine clinical outcomes in patients with eosinophilic asthma and autoimmune disease that received dual biologic therapy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Feb 2023
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary) ; Certolizumab pegol (Primary) ; Etanercept (Primary) ; Mepolizumab (Primary) ; Rituximab (Primary) ; Secukinumab (Primary)
- Indications Asthma; Autoimmune disorders; Non-radiographic axial spondyloarthritis; Psoriatic arthritis; Rheumatoid arthritis
- Focus Adverse reactions; Therapeutic Use
- 06 Feb 2023 New trial record